Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer

REFERENCES

• Nielsen M. E., Partin A. W. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol 2007; 9(2)57–62
   PubMedGoogle Scholar
• Nguyen P. L., Chen M. H., Catalona W. J., Moul J. W., Sun L., D'Amico A. V. Predicting prostate cancer mortality Among men with intermediate to high-risk disease and multiple unfavorable risk factors. Int J Radiat Oncol Biol Phys 2008
   Web of Science ®Google Scholar
• D'Amico A. V., Hui-Chen M., Renshaw A. A., Sussman B., Roehl K. A., Catalona W. J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 2006; 176(6 Pt 2)S11–15
   PubMed Web of Science ®Google Scholar
• Thompson R. H., Blute M. L., Slezak J. M., Bergstralh E. J., Leibovich B. C. Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?. J Urol 2007; 178(2)459–463, discussion 463
   PubMed Web of Science ®Google Scholar
• Eastham J. A., Scardino P. T., Kattan M. W. Predicting an optimal outcome after radical prostatectomy: the Trifecta nomogram. J Urol 2008; 179(6)2207–2210, discussion 2210–2201
   PubMed Web of Science ®Google Scholar
• Roberts W. W., Bergstralh E. J., Blute M. L., Slezak J. M., Carducci M., Han M., Epstein J. I., Eisenberger M. A., Walsh P. C., Partin A. W. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57(6)1033–1037
   PubMed Web of Science ®Google Scholar
• Stephenson A. J., Scardino P. T., Eastham J. A., Bianco F. J., Jr., Dotan Z. A., Fearn P. A., Kattan M. W. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98(10)715–717
   PubMed Web of Science ®Google Scholar
• D'Amico A. V., Chen M. H., Roehl K. A., Catalona W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351(2)125–135
   PubMed Web of Science ®Google Scholar
• Hanks G. E., Hanlon A. L., Lee W. R., Slivjak A., Schultheiss T. E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 1996; 34(3)549–553
   PubMed Web of Science ®Google Scholar
• Sengupta S., Myers R. P., Slezak J. M., Bergstralh E. J., Zincke H., Blute M. L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005; 174(6)2191–2196
   PubMed Web of Science ®Google Scholar
• Thompson I. M., Pauler D. K., Goodman P. J., Tangen C. M., Lucia M. S., Parnes H. L., Minasian L. M., Ford L. G., Lippman S. M., Crawford E. D., Crowley J. J., Coltman C. A., Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350(22)2239–2246
   PubMed Web of Science ®Google Scholar
• Blute M. L., Bergstralh E. J., Iocca A., Scherer B., Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165(1)119–125
   PubMed Web of Science ®Google Scholar
• Jones P. A., Baylin S. B. The epigenomics of cancer. Cell 2007; 128(4)683–692
   PubMed Web of Science ®Google Scholar
• Laird P. W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3(4)253–266
   PubMed Web of Science ®Google Scholar
• Ting A. H., McGarvey K. M., Baylin S. B. The cancer epigenome—components and functional correlates. Genes Dev 2006; 20(23)3215–3231
   PubMed Web of Science ®Google Scholar
• Brueckner B., Kuck D., Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J 2007; 13(1)17–22
   PubMed Web of Science ®Google Scholar
• Egger G., Liang G., Aparicio A., Jones P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429(6990)457–463
   PubMed Web of Science ®Google Scholar
• Moggs J. G., Goodman J. I., Trosko J. E., Roberts R. A. Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol Appl Pharmacol 2004; 196(3)422–430
   PubMed Web of Science ®Google Scholar
• Yoo C. B., Jones P. A. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5(1)37–50
   PubMed Web of Science ®Google Scholar
• Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L. C., Kawahara M., Nakagawa M., Kane C. J., Carroll P. R., Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005; 11(18)6582–6588
   PubMed Web of Science ®Google Scholar
• Vanaja D. K., Ballman K. V., Morlan B. W., Cheville J. C., Neumann R. M., Lieber M. M., Tindall D. J., Young C. Y. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006; 12(4)1128–1136
   PubMed Web of Science ®Google Scholar
• Vanaja D. K., Cheville J. C., Iturria S. J., Young C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63(14)3877–3882
   PubMed Web of Science ®Google Scholar
• Ehrich M., Field J. K., Liloglou T., Xinarianos G., Oeth P., Nelson M. R., Cantor C. R., van den Boom D. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res 2006; 66(22)10911–10918
   PubMed Web of Science ®Google Scholar
• Freedland S. J., Aronson W. J., Presti J. C., Jr., Amling C. L., Terris M. K., Trock B., Kane C. J. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004; 100(8)1633–1638
   PubMed Web of Science ®Google Scholar
• Stephenson A. J., Kattan M. W., Eastham J. A., Dotan Z. A., Bianco F. J., Jr., Lilja H., Scardino P. T. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24(24)3973–3978
   PubMed Web of Science ®Google Scholar
• Kupelian P. A., Elshaikh M., Reddy C. A., Zippe C., Klein E. A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002; 20(16)3376–3385
   PubMed Web of Science ®Google Scholar
• Freedland S. J., Sutter M. E., Dorey F., Aronson W. J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61(2)365–369
   Google Scholar
• Boorjian S. A., Karnes R. J., Rangel L. J., Bergstralh E. J., Blute M. L. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008; 179(4)1354–1360, discussion 1360–1351
   PubMed Web of Science ®Google Scholar
• Takai D., Jones P. A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 2002; 99(6)3740–3745
   PubMed Web of Science ®Google Scholar
• Gardiner-Garden M., Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196(2)261–282
   PubMed Web of Science ®Google Scholar
• Goessl C., Krause H., Muller M., Heicappell R., Schrader M., Sachsinger J., Miller K. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60(21)5941–5945
   PubMed Web of Science ®Google Scholar
• Hanson J. A., Gillespie J. W., Grover A., Tangrea M. A., Chuaqui R. F., Emmert-Buck M. R., Tangrea J. A., Libutti S. K., Linehan W. M., Woodson K. G. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006; 98(4)255–261
   PubMed Web of Science ®Google Scholar
• Hampton T. New markers may help predict prostate cancer relapse risk. JAMA 2006; 295(19)2234–2238
   PubMed Web of Science ®Google Scholar
• Li L. C., Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18(11)1427–1431
   PubMed Web of Science ®Google Scholar
• Jornsten R., Yu B. Simultaneous gene clustering and subset selection for sample classification via MDL. Bioinformatics 2003; 19(9)1100–1109
   PubMed Web of Science ®Google Scholar
• Hess K. R., Anderson K., Symmans W. F., Valero V., Ibrahim N., Mejia J. A., Booser D., Theriault R. L., Buzdar A. U., Dempsey P. J., Rouzier R., Sneige N., Ross J. S., Vidaurre T., Gomez H. L., Hortobagyi G. N., Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24(26)4236–4244
   PubMed Web of Science ®Google Scholar
• Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99(10)6567–6572
   PubMed Web of Science ®Google Scholar
• Yu Y. P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., Luo J. H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22(14)2790–2799
   PubMed Web of Science ®Google Scholar
• Singh D., Febbo P. G., Ross K., Jackson D. G., Manola J., Ladd C., Tamayo P., Renshaw A. A., D'Amico A. V., Richie J. P., Lander E. S., Loda M., Kantoff P. W., Golub T. R., Sellers W. R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1(2)203–209
   PubMed Web of Science ®Google Scholar
• Lapointe J., Li C., Higgins J. P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., Ekman P., DeMarzo A. M., Tibshirani R., Botstein D., Brown P. O., Brooks J. D., Pollack J. R. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101(3)811–816
   PubMed Web of Science ®Google Scholar
• Dhanasekaran S. M., Barrette T. R., Ghosh D., Shah R., Varambally S., Kurachi K., Pienta K. J., Rubin M. A., Chinnaiyan A. M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412(6849)822–826
   PubMed Web of Science ®Google Scholar
• Bastian P. J., Palapattu G. S., Lin X., Yegnasubramanian S., Mangold L. A., Trock B., Eisenberger M. A., Partin A. W., Nelson W. G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11(11)4037–4043
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S., Kowalski J., Gonzalgo M. L., Zahurak M., Piantadosi S., Walsh P. C., Bova G. S., De Marzo A. M., Isaacs W. B., Nelson W. G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64(6)1975–1986
   PubMed Web of Science ®Google Scholar
• Li L. C., Carroll P. R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97(2)103–115
   PubMed Web of Science ®Google Scholar
• Lotan R., Lotan Y. Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy. Clin Cancer Res 2004; 10(12 Pt 1)3935–3936
   PubMed Web of Science ®Google Scholar
• Lin X., Tascilar M., Lee W. H., Vles W. J., Lee B. H., Veeraswamy R., Asgari K., Freije D., van Rees B., Gage W. R., Bova G. S., Isaacs W. B., Brooks J. D., DeWeese T. L., De Marzo A. M., Nelson W. G. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001; 159(5)1815–1826
   PubMed Web of Science ®Google Scholar
• Henrique R., Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46(5)660–669, ; discussion 669
   PubMed Web of Science ®Google Scholar
• Bernardini S., Miano R., Iori R., Finazzi-Agro E., Palmieri G., Ballerini S., Angeloni C., Orlandi A., Bellincampi L., Cortese C., Federici G. Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?. Clin Chim Acta 2004; 350(1–2)181–188
   PubMed Web of Science ®Google Scholar
• Bastian P. J., Nakayama M., De Marzo A. M., Nelson W. G. [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A 2004; 43(5)573–579
   PubMedGoogle Scholar
• Rosenbaum E., Hoque M. O., Cohen Y., Zahurak M., Eisenberger M. A., Epstein J. I., Partin A. W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11(23)8321–8325
   PubMed Web of Science ®Google Scholar
• Jeronimo C., Henrique R., Hoque M. O., Mambo E., Ribeiro F. R., Varzim G., Oliveira J., Teixeira M. R., Lopes C., Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10(24)8472–8478
   PubMed Web of Science ®Google Scholar
• Kang G. H., Lee S., Lee H. J., Hwang K. S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202(2)233–240
   PubMed Web of Science ®Google Scholar
• Bastian P. J., Ellinger J., Heukamp L. C., Kahl P., Muller S. C., von Rucker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51(3)665–674
   PubMed Web of Science ®Google Scholar
• Varambally S., Yu J., Laxman B., Rhodes D. R., Mehra R., Tomlins S. A., Shah R. B., Chandran U., Monzon F. A., Becich M. J., Wei J. T., Pienta K. J., Ghosh D., Rubin M. A., Chinnaiyan A. M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8(5)393–406
   PubMed Web of Science ®Google Scholar
• Nakajima T., Maekita T., Oda I., Gotoda T., Yamamoto S., Umemura S., Ichinose M., Sugimura T., Ushijima T., Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006; 15(11)2317–2321
   PubMed Web of Science ®Google Scholar
• Maier S., Nimmrich I., Koenig T., Eppenberger-Castori S., Bohlmann I., Paradiso A., Spyratos F., Thomssen C., Mueller V., Nahrig J., Schittulli F., Kates R., Lesche R., Schwope I., Kluth A., Marx A., Martens J. W., Foekens J. A., Schmitt M., Harbeck N. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients—technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer 2007; 43(11)1679–1686
   PubMed Web of Science ®Google Scholar
• Ohba T., Ishino M., Aoto H., Sasaki T. Dot far-western blot analysis of relative binding affinities of the Src homology 3 domains of Efs and its related proteins. Anal Biochem 1998; 262(2)185–192
   PubMed Web of Science ®Google Scholar
• Yue C. M., Deng D. J., Bi M. X., Guo L. P., Lu S. H. Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma. World J Gastroenterol 2003; 9(6)1174–1178
   PubMed Web of Science ®Google Scholar